The stem cell market size has grown strongly in recent years. It will grow from $16.85 billion in 2025 to $18.51 billion in 2026 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to advancements in cell biology research, expansion of clinical trials in regenerative medicine, increasing use of stem cells in drug discovery, growth of biobanking infrastructure, rising investment in life sciences research.
The stem cell market size is expected to see rapid growth in the next few years. It will grow to $29.1 billion in 2030 at a compound annual growth rate (CAGR) of 12%. The growth in the forecast period can be attributed to increasing approval of stem cell-based therapies, rising demand for personalized medicine, expansion of large-scale stem cell manufacturing, growing integration of automation in cell processing, increasing global healthcare investment. Major trends in the forecast period include increasing advancement of regenerative medicine therapies, rising adoption of induced pluripotent stem cells, growing integration of ai in cell research and development, expansion of stem cell banking services, enhanced focus on standardized manufacturing processes.
There is a rising prevalence of chronic diseases across the globe, which is contributing to the growth of the stem cell market. Stem cell therapy involves the use of stem cells to treat or prevent various diseases or medical conditions. The most commonly used form of stem cell therapy is bone marrow transplantation, although certain therapies derived from umbilical cord blood are also being utilized. At present, the most widely applied stem cell treatments involve the transplantation of blood stem cells to manage diseases and disorders of the blood and immune system or to restore blood production following treatments for certain cancers. For example, in July 2024, data from the Australian Institute of Health and Welfare (AIHW), an Australia-based government health statistics agency, indicated that chronic conditions were responsible for 78% of the fatal disease burden, reflecting an increase compared to previous years. Consequently, the growing prevalence of chronic diseases worldwide is driving the expansion of the stem cell market.
Major companies operating in the stem cell market are concentrating on the development of advanced solutions, including allogeneic cord blood and mesenchymal stem cell (MSC) therapies, to strengthen their competitive position. Allogeneic cord blood therapies utilize hematopoietic stem cells obtained from donated umbilical cord blood to regenerate or rebuild the blood and immune systems of patients with hematological or immunological conditions. For example, in November 2024, StemCyte Inc., a biotechnology company based in the United States, introduced REGENECYTE, an allogeneic cord blood stem cell therapy designed for transplantation in patients with blood and immune system disorders. REGENECYTE provides donor-derived progenitor cells that are banked and readily available, supporting off-the-shelf treatment and minimizing delays related to donor matching and cell harvesting. This development expands access for patients who do not have suitable donors and facilitates treatment scalability, although it may present challenges related to supply chain coordination and consistency of long-term engraftment.
In April 2023, STEMCELL Technologies, a Canada-based biotechnology company, acquired SQZ Biotechnologies Company for an undisclosed sum. This acquisition is expected to strengthen STEMCELL’s cell therapy delivery capabilities by incorporating SQZ’s proprietary mechanoporation technology, which enables the delivery of therapeutic cargo into cells without the use of electrical methods. SQZ Biotechnologies, headquartered in the United States, focuses on developing novel approaches for introducing therapeutic payloads into cells through mechanoporation. SQZ Biotechnologies Co. operates as a US-based clinical-stage biotechnology company.
Major companies operating in the stem cell market are Danaher Corporation, Cryo-Cell International Inc., Daiichi Sankyo Company Limited, Lonza Group Ltd, PerkinElmer Inc., CellGenix GmbH, China Cord Blood Corporation, Organogenesis Holdings Inc., LifeCell International, Cord Blood America Inc., StemCyte Inc., Cryoviva India, Cordlife Group Limited, Thermo Fisher Scientific Inc., CordVida, Cryo Stemcell Inc., Pluristem Therapeutics Inc., Mesoblast Limited, Americord Registry LLC, Smart Cells International, Athersys Inc., ReeLabs Pvt. Ltd., Cytori Therapeutics Inc., Esperite N.V., Stemade Biotech, ViaCord, Aldagen Inc, Isto Biologics, Brainstorm Cell Therapeutics Inc.
North America was the largest region in the stem cell market in 2025. Western Europe was the second largest region in the global stem cell market share. The regions covered in the stem cell market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the stem cell market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the stem cell market by increasing costs of imported laboratory equipment, bioreactors, reagents, cryopreservation systems, and advanced manufacturing tools. Research institutions and biotech firms in North America and Europe are most affected due to reliance on imported precision equipment, while Asia-Pacific faces higher costs in export-oriented bioprocessing. These tariffs can raise research and production expenses. However, they are also driving domestic equipment manufacturing, regional supply chain development, and localized production of critical stem cell processing technologies.
The stem cell market research report is one of a series of new reports that provides stem cell market statistics, including stem cell industry global market size, regional shares, competitors with a stem cell market share, detailed stem cell market segments, market trends and opportunities, and any further data you may need to thrive in the stem cell industry. This stem cell market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Stem cells are autologous or allogeneic cells capable of differentiating into multiple cell types both in vivo and in vitro. They play a significant role in the medical treatment of injuries and damage to organs.
The primary product types of stem cells include adult stem cells, human embryonic stem cells, induced pluripotent stem cells, and others. Adult stem cells are a small population of cells present in the body throughout most of postnatal life and can generate a limited range of mature cell types that make up the tissue in which they reside. These cells can be sourced as autologous or allogeneic and are utilized across various applications, including regenerative medicine, drug discovery, and development.
The stem cell market consists of sales of organoids & 3D Cell Culture, mesenchymal Stem Cells, neural stem cells, hematopoietic stem cells, and cancer stem cells. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The stem cell market size is expected to see rapid growth in the next few years. It will grow to $29.1 billion in 2030 at a compound annual growth rate (CAGR) of 12%. The growth in the forecast period can be attributed to increasing approval of stem cell-based therapies, rising demand for personalized medicine, expansion of large-scale stem cell manufacturing, growing integration of automation in cell processing, increasing global healthcare investment. Major trends in the forecast period include increasing advancement of regenerative medicine therapies, rising adoption of induced pluripotent stem cells, growing integration of ai in cell research and development, expansion of stem cell banking services, enhanced focus on standardized manufacturing processes.
There is a rising prevalence of chronic diseases across the globe, which is contributing to the growth of the stem cell market. Stem cell therapy involves the use of stem cells to treat or prevent various diseases or medical conditions. The most commonly used form of stem cell therapy is bone marrow transplantation, although certain therapies derived from umbilical cord blood are also being utilized. At present, the most widely applied stem cell treatments involve the transplantation of blood stem cells to manage diseases and disorders of the blood and immune system or to restore blood production following treatments for certain cancers. For example, in July 2024, data from the Australian Institute of Health and Welfare (AIHW), an Australia-based government health statistics agency, indicated that chronic conditions were responsible for 78% of the fatal disease burden, reflecting an increase compared to previous years. Consequently, the growing prevalence of chronic diseases worldwide is driving the expansion of the stem cell market.
Major companies operating in the stem cell market are concentrating on the development of advanced solutions, including allogeneic cord blood and mesenchymal stem cell (MSC) therapies, to strengthen their competitive position. Allogeneic cord blood therapies utilize hematopoietic stem cells obtained from donated umbilical cord blood to regenerate or rebuild the blood and immune systems of patients with hematological or immunological conditions. For example, in November 2024, StemCyte Inc., a biotechnology company based in the United States, introduced REGENECYTE, an allogeneic cord blood stem cell therapy designed for transplantation in patients with blood and immune system disorders. REGENECYTE provides donor-derived progenitor cells that are banked and readily available, supporting off-the-shelf treatment and minimizing delays related to donor matching and cell harvesting. This development expands access for patients who do not have suitable donors and facilitates treatment scalability, although it may present challenges related to supply chain coordination and consistency of long-term engraftment.
In April 2023, STEMCELL Technologies, a Canada-based biotechnology company, acquired SQZ Biotechnologies Company for an undisclosed sum. This acquisition is expected to strengthen STEMCELL’s cell therapy delivery capabilities by incorporating SQZ’s proprietary mechanoporation technology, which enables the delivery of therapeutic cargo into cells without the use of electrical methods. SQZ Biotechnologies, headquartered in the United States, focuses on developing novel approaches for introducing therapeutic payloads into cells through mechanoporation. SQZ Biotechnologies Co. operates as a US-based clinical-stage biotechnology company.
Major companies operating in the stem cell market are Danaher Corporation, Cryo-Cell International Inc., Daiichi Sankyo Company Limited, Lonza Group Ltd, PerkinElmer Inc., CellGenix GmbH, China Cord Blood Corporation, Organogenesis Holdings Inc., LifeCell International, Cord Blood America Inc., StemCyte Inc., Cryoviva India, Cordlife Group Limited, Thermo Fisher Scientific Inc., CordVida, Cryo Stemcell Inc., Pluristem Therapeutics Inc., Mesoblast Limited, Americord Registry LLC, Smart Cells International, Athersys Inc., ReeLabs Pvt. Ltd., Cytori Therapeutics Inc., Esperite N.V., Stemade Biotech, ViaCord, Aldagen Inc, Isto Biologics, Brainstorm Cell Therapeutics Inc.
North America was the largest region in the stem cell market in 2025. Western Europe was the second largest region in the global stem cell market share. The regions covered in the stem cell market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the stem cell market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the stem cell market by increasing costs of imported laboratory equipment, bioreactors, reagents, cryopreservation systems, and advanced manufacturing tools. Research institutions and biotech firms in North America and Europe are most affected due to reliance on imported precision equipment, while Asia-Pacific faces higher costs in export-oriented bioprocessing. These tariffs can raise research and production expenses. However, they are also driving domestic equipment manufacturing, regional supply chain development, and localized production of critical stem cell processing technologies.
The stem cell market research report is one of a series of new reports that provides stem cell market statistics, including stem cell industry global market size, regional shares, competitors with a stem cell market share, detailed stem cell market segments, market trends and opportunities, and any further data you may need to thrive in the stem cell industry. This stem cell market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Stem cells are autologous or allogeneic cells capable of differentiating into multiple cell types both in vivo and in vitro. They play a significant role in the medical treatment of injuries and damage to organs.
The primary product types of stem cells include adult stem cells, human embryonic stem cells, induced pluripotent stem cells, and others. Adult stem cells are a small population of cells present in the body throughout most of postnatal life and can generate a limited range of mature cell types that make up the tissue in which they reside. These cells can be sourced as autologous or allogeneic and are utilized across various applications, including regenerative medicine, drug discovery, and development.
The stem cell market consists of sales of organoids & 3D Cell Culture, mesenchymal Stem Cells, neural stem cells, hematopoietic stem cells, and cancer stem cells. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Stem Cell Market Characteristics
3. Stem Cell Market Supply Chain Analysis
4. Global Stem Cell Market Trends and Strategies
5. Stem Cell Market Analysis of End Use Industries
7. Global Stem Cell Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Stem Cell Total Addressable Market (TAM) Analysis for the Market
9. Stem Cell Market Segmentation
10. Stem Cell Market Regional and Country Analysis
11. Asia-Pacific Stem Cell Market
12. China Stem Cell Market
13. India Stem Cell Market
14. Japan Stem Cell Market
15. Australia Stem Cell Market
16. Indonesia Stem Cell Market
17. South Korea Stem Cell Market
18. Taiwan Stem Cell Market
19. South East Asia Stem Cell Market
20. Western Europe Stem Cell Market
21. UK Stem Cell Market
22. Germany Stem Cell Market
23. France Stem Cell Market
24. Italy Stem Cell Market
25. Spain Stem Cell Market
26. Eastern Europe Stem Cell Market
27. Russia Stem Cell Market
28. North America Stem Cell Market
29. USA Stem Cell Market
30. Canada Stem Cell Market
31. South America Stem Cell Market
32. Brazil Stem Cell Market
33. Middle East Stem Cell Market
34. Africa Stem Cell Market
36. Stem Cell Market Competitive Landscape and Company Profiles
37. Stem Cell Market Other Major and Innovative Companies
40. Stem Cell Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Stem Cell Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses stem cell market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for stem cell? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The stem cell market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Source: Autologous; Allogeneic2) By Product Type: Adult Stem Cell; Human Embryonic Stem Cell; Induced Pluripotent Stem Cell; Other Products
3) By Application: Regenerative Medicine; Drug Discovery And Development
Subsegments:
1) By Autologous: Bone Marrow-Derived Stem Cells; Adipose Tissue-Derived Stem Cells; Peripheral Blood Stem Cells2) By Allogeneic: Bone Marrow-Derived Stem Cells; Umbilical Cord Blood Stem Cells; Peripheral Blood Stem Cells From Donors
Companies Mentioned: Danaher Corporation; Cryo-Cell International Inc.; Daiichi Sankyo Company Limited; Lonza Group Ltd; PerkinElmer Inc.; CellGenix GmbH; China Cord Blood Corporation; Organogenesis Holdings Inc.; LifeCell International; Cord Blood America Inc.; StemCyte Inc.; Cryoviva India; Cordlife Group Limited; Thermo Fisher Scientific Inc.; CordVida; Cryo Stemcell Inc.; Pluristem Therapeutics Inc.; Mesoblast Limited; Americord Registry LLC; Smart Cells International; Athersys Inc.; ReeLabs Pvt. Ltd.; Cytori Therapeutics Inc.; Esperite N.V.; Stemade Biotech; ViaCord; Aldagen Inc; Isto Biologics; Brainstorm Cell Therapeutics Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Stem Cell market report include:- Danaher Corporation
- Cryo-Cell International Inc.
- Daiichi Sankyo Company Limited
- Lonza Group Ltd
- PerkinElmer Inc.
- CellGenix GmbH
- China Cord Blood Corporation
- Organogenesis Holdings Inc.
- LifeCell International
- Cord Blood America Inc.
- StemCyte Inc.
- Cryoviva India
- Cordlife Group Limited
- Thermo Fisher Scientific Inc.
- CordVida
- Cryo Stemcell Inc.
- Pluristem Therapeutics Inc.
- Mesoblast Limited
- Americord Registry LLC
- Smart Cells International
- Athersys Inc.
- ReeLabs Pvt. Ltd.
- Cytori Therapeutics Inc.
- Esperite N.V.
- Stemade Biotech
- ViaCord
- Aldagen Inc
- Isto Biologics
- Brainstorm Cell Therapeutics Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 18.51 Billion |
| Forecasted Market Value ( USD | $ 29.1 Billion |
| Compound Annual Growth Rate | 12.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 30 |
